U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from acquiring contract drug manufacturer Catalent,

The coalition said in a letter sent to the FTC Thursday that the deal could reduce access to GLP-1s, and harm competition in development of cell and gene therapies.

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.

Five U.S. consumer groups and two big labor unions are pushing for the Federal Trade Commission to block Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT), arguing that a deal would hurt competition in weigh-loss drugs.